Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes

Cancer Letters

Volumn 255, Issue 1, 2007, Pages 49-56

  Plebuch, Mariann ^a   Soldan, Michael ^a   Hungerer, Christoph ^a   Koch, Lutz ^a   Maser, Edmund ^a,b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Aldo keto reductase; Carbonyl reductase; Cardiotoxicity; Daunorubicin; Daunorubicinol; Drug resistance

Indexed keywords

ALDEHYDE REDUCTASE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC ANTIBIOTIC; BETA 2 MICROGLOBULIN; CARBONYL REDUCTASE; COMPLEMENTARY DNA; DAUNORUBICIN; DAUNORUBICINOL; DRUG METABOLITE; RNA;

ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ALCOHOL OXIDOREDUCTASES; ALDEHYDE REDUCTASE; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CLONING, MOLECULAR; DAUNORUBICIN; DNA, COMPLEMENTARY; DRUG RESISTANCE; HUMANS; INHIBITORY CONCENTRATION 50; PANCREATIC NEOPLASMS; TETRAZOLIUM SALTS; THIAZOLES; TRANSFECTION;

EID: 34547679864     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.03.018     Document Type: Article

References (47)

1. Endicott J.A., and Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58 (1989) 137-171
2. Scheffer G.L., Wijngaard P.L.J., Flens M.J., Izquierdo M.A., Slovak M.L., Pinedo H.M., Meijer C.J.L.M., Clevers H.C., and Scheper R.J. The drug resistance-related protein LRP is the human major vault protein. Nature Med. 1 (1995) 578-582
3. Zaman G.J.R., Flens M.J., van Leusden M.R., de Haas M., Mülder H.S., Lankelma J., Pinedo H.M., Scheper R.J., Baas F., Broxterman H.J., and Borst P. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA 91 (1994) 8822-8826
4. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 112 (2006) 457-473
5. Takara K., Sakaeda T., and Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr. Pharm. Des. 12 (2006) 273-286
6. Rekha G.K., Sreerama L., and Sladek N.E. Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase. Biochem. Pharmacol. 48 (1994) 1943-1952
7. Gessner T., Vaughan L.A., Beehler B.C., Bartels C.J., and Baker R.M. Elevated pentose cycle and glucuronyltransferase in daunorubicin-resistant P388 cells. Cancer Res. 50 (1990) 3921-3927
8. Batist G., Tulpule A., Sinha B.K., Katki A.G., Myers G.E., and Cowans K.H. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J. Biol. Chem. 261 (1986) 15544-15549
9. Bosch T.M., Meijerman I., Beijnen J.H., and Schellens J.H. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin. Pharmacokinet. 45 (2006) 253-285
10. Cummings J., Ethell B.T., Jardine L., Boyd G., Macpherson J.S., Burchell B., Smyth J.F., and Jodrell D.I. Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res. 63 (2003) 8443-8450
11. Weiss R.B. The anthracyclines: will we ever find a better doxorubicin?. Semin. Oncol. 19 (1992) 670-686
12. Rabbani A., Finn R.M., and Ausio J. The anthracycline antibiotics: antitumor drugs that alter chromatin structure. Bioassays 27 (2005) 50-56
13. Minotti G., Menna P., Salvatorelli E., Cairo G., and Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56 (2004) 185-229
14. Zucchi R., and Danesi R. Cardiac toxicity of antineoplastic anthracyclines. Curr. Med. Chem. Anticancer Agents 3 (2003) 151-171
15. Ax W., Soldan M., Koch L., and Maser E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem. Pharmacol. 59 (2000) 293-300
16. Soldan M., Ax W., Plebuch M., Koch L., and Maser E. Cytostatic drug resistance. Role of phase-I daunorubicin metabolism in cancer cells. Adv. Exp. Med. Biol. 463 (1999) 529-538
17. Soldan M., Netter K.J., and Maser E. Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive and resistant pancreas carcinoma cells. Biochem. Pharmacol. 51 (1996) 117-123
18. Schott B., and Robert J. Comparative activity of anthracycline 13-hydroxymetabolites against rat glioblastoma cells in culture. Biochem. Pharmacol. 38 (1989) 4069-4074
19. Olson R.D., Mushlin P.S., Brenner D.E., Fleischer S., Cusack B.J., Chang B.K., and Boucek Jr. R.J. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc. Natl. Acad. Sci. USA 85 (1988) 3585-3589
20. Kuffel M.J., Reid J.M., and Ames M.M. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother. Pharmacol. 30 (1992) 51-57
21. Licata S., Saponiero A., Mordente A., and Minotti G. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Chem. Res. Toxicol. 13 (2000) 414-420
22. Mordente A., Minotti G., Martorana G.E., Silvestrini A., Giardina B., and Meucci E. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. Biochem. Pharmacol. 66 (2003) 989-998
23. Forrest G.L., and Gonzalez B. Carbonyl reductase. Chem. Biol. Interact. 129 (2000) 21-40
24. Forrest G.L., Gonzalez B., Tseng W., Li X., and Mann J. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res. 60 (2000) 5158-5164
25. Li X., Cusack B.J., Boucek Jr. R.J., Mushlin P.S., Bledsoe T.B., Brenner D.E., and Olson R.D. Effects of daunorubicin and its primary metabolite, daunorubicinol, on cardiac contractility and calcium loading of sarcoplasmic reticulum. FASEB J. 5 (1991) A1395 Abstract
26. Olson R.D., and Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 4 (1990) 3076-3086
27. Jörnvall H., Persson B., Krook M., Atrian S., Gonzalez-Duarte R., Jeffery J., and Ghosh D. Short-chain dehydrogenases/reductases (SDR). Biochemistry 34 (1995) 6003-6013
28. Jez J.M., Flynn T.G., and Penning T.M. A new nomenclature for the aldo-keto reductase superfamily. Biochem. Pharmacol. 54 (1997) 639-647
29. Oppermann U. Carbonyl reductases: the complex relationships of Mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 293-322
30. Hoffmann F., and Maser E. Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab. Rev. 39 (2007) 87-144
31. Jin Y., and Penning T.M. Aldo-keto reductases and bioactivation/detoxication. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 263-292
32. Matsunaga T., Shintani S., and Hara A. Multiplicity of mammalian reductases for xenobiotic carbonyl compounds. Drug Metab. Pharmacokinet. 21 (2006) 1-18
33. Ohara H., Miyabe Y., Deyashiki Y., Matsuura K., and Hara A. Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem. Pharmacol. 50 (1995) 221-227
34. Lee K.W., Ko B.C., Jiang Z., Cao D., and Chung S.S. Overexpression of aldose reductase in liver cancers may contribute to drug resistance. Anticancer Drugs 12 (2001) 129-132
35. Toffoli G., Simone F., Gigante M., and Boiocchi M. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines. Biochem. Pharmacol. 48 (1994) 1871-1881
36. McGrath T., and Center M.S. Adriamycin resistance in HL60 cells in absence of detectable P-glycoprotein. Biochem. Biophys. Res. Com. 145 (1987) 1171-1176
37. Ramachandran C., Yuan Z.K., Huang X.L., and Krishan A. Doxorubicin resistance in human melanoma cells: MDR-1 and glutathione S-transferase π gene expression. Biochem. Pharmacol. 45 (1993) 743-751
38. Forrest G.L., Akman S., Krutzik S., Paxton R.J., Sparkes R.S., Doroshow J., Felsted R.L., Glover C.J., Mohandas T., and Bachur N.R. Induction of a human carbonyl reductase gene located on chromosome 21. Biochim. Biophys. Acta 1048 (1990) 149-155
39. Hyndman D.J., Takenoshita R., Vera N.L., Pang S.C., and Flynn T.G. Cloning and sequencing, and enzymatic activity of an inducible aldo-keto reductase from Chinese hamster ovary cells. J. Biol. Chem. 272 (1997) 13286-13291
40. Lage H., and Dietel M. Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells. J. Cancer Res. Clin. Oncol. 128 (2002) 349-357
41. Gonzalez B., Akman S., Doroshow J., Rivera H., Kaplan W.D., and Forrest G.L. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. Cancer Res. 55 (1995) 4646-4650
42. Wermuth B., Bohren K.M., Heinemann G., von Wartburg J.P., and Gabbay K.H. Human carbonyl reductase. Nucleotide sequence analysis of a cDNA and amino acid sequence of the encoded protein. J. Biol. Chem. 263 (1988) 16185-16188
43. Wermuth B., Platt K.L., Seidel A., and Oesch F. Carbonyl reductase provides the enzymatic basis of quinone detoxication in man. Biochem. Pharmacol. 35 (1986) 1277-1282
44. Srivastava S.K., Ramana K.V., and Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev. 26 (2005) 380-392
45. Takahashi M., Fujii J., Miyoshi E., Hoshi A., and Taniguchi N. Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: implication in detoxification of cytotoxic aldehydes. Int. J. Cancer 62 (1995) 749-754
46. Mordente A., Meucci E., Martorana G.E., Giardina B., and Minotti G. Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 52 (2001) 83-88
47. Olson L.E., Bedja D., Alvey S.J., Cardounel A.J., Gabrielson K.L., and Reeves R.H. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res. 63 (2003) 6602-6606